Phesgo and Tecentriq Performance and Approvals

Q1 2023: Regional Pharma and Group sales bridge +6% +5% +13% +18% -28% -3% -7% Pharma Division +9% +366 +224 +101 +286 -1,480 -503 -1,123 -620 United States Europe Intl. Chugai Dia Division Group Fx1 Group (Japan) CHF Absolute values in CHFm at Constant Exchange Rates (avg full year 2022); 1 avg. full year 2022 to avg Q1 2023 fx impact Roche 45 445

View entire presentation